MedTrace Logo

Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release

NCT00655915 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-03-09

No results posted yet for this study

Summary

This study will investigate whether symptomatic improvement following carpal tunnel corticosteroid injection can be correlated to symptomatic improvement following carpal tunnel release and therefore serve as a prognostic indicator.

Clinical question: Does response to corticosteroid injection in CTS predict outcomes of surgical treatment?

Secondary Questions:

1. Can we confirm previous retrospectively collected data that a certain percentage of conservatively managed patients with steroid injection will avoid surgery, and that patients who undergo surgery will have better outcomes than those who do not.
2. Are there differences between worker's compensation and non-worker's compensation patients with regard to the primary clinical question?
3. What are Carpal Tunnel Release outcomes for the subset of patients with negative electrophysiologic studies?
4. What are the outcomes of patients who undergo carpal tunnel release vs. those who choose not to undergo carpal tunnel release?

A prospective cohort design study is the appropriate study design in order to measure the association between a predictor (response to injection) and outcome (response to surgery).

Conditions

  • Carpal Tunnel Syndrome

Interventions

OTHER

Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine

Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Jeffry T Watson, M.D. · Vanderbilt University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655915 on ClinicalTrials.gov